Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

By B. Haffty, Qifeng Yang, M. Reiss, T. Kearney, S. Higgins, J. Weidhaas, L. Harris, W. Hait, D. Toppmeyer. Journal of Clinical Oncology, 2006

1,093 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/c017a166d920ae1795c30ad6bde50d3f185ec01c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Padmanee Sharma
2. X. Chen
3. S. Leung
4. Charles M. Perou
5. Torsten O. Nielsen
6. M. J. van de Vijver

In Genetics

1. X. Chen

Citations in the corpus

• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. (2016, background): “TNBC tumors are frequently of high histologic grade,(7,9) present at an advanced stage,(7,9) are typically more aggressive and difficult to treat than hormone receptor–positive tumors,(2,10) and are associated with a higher risk of early relapse.(2,10) The lack of estrogen receptor, progesterone rec”
• Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype (2008, background): “Other studies (8, 14, 35) have reported that the basal-like subtype is a potential candidate to respond well to chemotherapy.”
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. (2011, background): “One of the first molecular insights into TNBCs was the observation that they are likely to arise in BRCA1 mutation carriers and have gene expression (GE) profiles similar to those of BRCA1-deficient tumors (5).”
• PD-L1 Expression in Triple Negative Breast Cancer (2014, positive): “TNBCs are generally high-grade, aggressive tumors with a high rate of distant metastasis and poorer disease-specific survival than other breast cancer subtypes (1, 3).”
• Triple-negative breast cancer--current status and future directions. (2009, background): “[41] N = 482 (118) 7.”
• Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer (2014, background): “Haffty et al.33 as well as Freedman et al.34 also found no significant differences in IBTR among patients treated with BCT when comparing TNBC with non-TNBC.”
• Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer (2008, result): “Previous reports have indicated that patients with early-stage basal-like or triple-negative breast cancers experience reduced disease-free and overall survival compared with other breast cancer subtypes.(2,5,6) In a retrospective study led by Haffty et al,(6) the triple-negative subtype was found t”
• Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas (2007, background): “It has been found that BRCA1-mutated breast carcinomas are almost always triple negative [37]; it would be interesting to know whether BRCA1 mutated tumors have a distinct gene-expression profile that distinguished them from the other basal type tumors.”